Skip to main content

Table 4 Time course of changes in serum beta-cell function during antiviral treatment of patients non- SVR

From: The association of hepatitis c virus infection status with serum glucose levels

 

Baseline

End-Rx

FU-24

P1 value

P2 value

FBG (mmol/l)

5.52 ± 0.83

4.93 ± 0.93

5.23 ± 0.74

< 0.001

0.023

FINS (μU/ml)

9.08 ± 4.88

9.05 ± 5.07

9.58 ± 5.12

0.546

0.888

FCP (nmol/l)

0.95 ± 0.33

0.97 ± 0.29

0.93 ± 0.31

0.609

0.819

HOMA-IR

2.27 ± 1.37

2.16 ± 1.42

2.49 ± 1.37

0.281

0.195

HOMA-β

104.5 ± 77.5

178.7 ± 148.3

144.3 ± 102.9

< 0.001

0.08

ISI

−3.77 ± 0.56

−3.69 ± 0.63

−3.87 ± 0.59

0.250

0.264

  1. Data are expressed as mean ± SD;
  2. FBG fasting blood glucose, FINS fasting insulin, FCP fasting C peptide, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β homeostasis model assessment for beta-cell function, ISI insulin sensitivity index, Rx treatment; FU-24, follow up at week 24 post treatment
  3. P1, value for comparison of baseline and end-Rx values; P2, value for comparison of baseline and FU-24 values
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us